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Abstract
Multiple-locus variable-number of tandem-repeats analysis (MLVA) has emerged as a valuable 
method for subtyping bacterial pathogens and has been adopted in many countries as a critical 
component of their laboratory-based surveillance. Lack of harmonisation and standardisation of 
the method, however, has made comparison of results generated in different laboratories difficult, 
if not impossible, and has therefore hampered its use in international surveillance. This paper 
proposes an international consensus on the development, validation, nomenclature and quality 
control for MLVA used for molecular surveillance and outbreak detection based on a review of the 
current state of knowledge.
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Multiple-locus variable-number of tandem-repeats analysis (MLVA) has recently emerged as 
a powerful method for the subtyping of food-borne bacterial pathogens. The method is based 
on repetitive DNA elements organised in tandem (Figure). DNA replication errors, such as 
slipped-strand mispairing, generate diversity in the number of tandem repeats observed 
among strains of the same species [1,2]. MLVA determines the number of tandem repeats, or 
copy units, at multiple variable-number tandem repeat (VNTR) loci within the genome. 
Typically, multiplex PCR amplification of the repeat and flanking regions is followed by 
amplicon sizing using capillary electrophoresis. The number of repeat copy units, or allele 
number, at each location is calculated from the measured amplicon size. The string of alleles 
from multiple loci forms the MLVA profile.
The recent development of MLVA protocols for subtyping food-borne bacterial pathogens, 
including Salmonella enterica serotypes Typhimurium and Enteritidis, and Shiga toxin-
producing Escherichia coli (STEC) O157:H7 has facilitated the implementation and 
application of MLVA for the successful detection and investigation of a wide variety of food-
borne disease outbreaks all over the world [3–6]. The early promise and success of MLVA 
triggered the independent development of multiple protocols by many different laboratories, 
leading to many different schemes for each organism. For example, six protocols have been 
described for STEC O157 [3, 7–11], six for S. Enteritidis [1, 12–16], and four for S. 
Typhimurium [17–20]. Differences in the choice of loci, nomenclature, amplicon sizing due 
to primer, platform and/or chemistry differences, and interpretation of incomplete or partial 
repeats have stymied and continue to stymie inter-laboratory comparisons and thus 
surveillance. A lack of standards for the development, validation and quality control/quality 
assurance of MLVA further contributes to problems in the comparison and interpretation of 
MLVA results.
The goal of any subtyping method is to characterise bacteria beyond the species (or 
subspecies) level and to group individual isolates together in a meaningful way. The ability 
to do this quickly and reliably is the cornerstone of laboratory-based surveillance [21]. 
Isolates that have indistinguishable subtypes are more likely to have originated from a 
common source than those with different subtypes. This concept forms the basis for 
applying molecular subtyping to bacterial pathogens for surveillance, outbreak detection and 
outbreak response.
To be suitable for laboratory-based surveillance and outbreak detection, a subtyping method 
should be assessed against several key performance criteria [21]: typeability, reproducibility, 
discriminatory power and epidemiological concordance. These criteria must be assessed 
using an epidemiologically relevant panel of isolates from geographically as diverse a region 
as where the method is to be applied. Additional criteria to assess method feasibility include 
speed, throughput, cost, ease of use, objectivity, versatility and portability. The importance 
of these criteria is further emphasised for the successful application of a subtyping method 
to inter-laboratory surveillance.
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While no single method will have perfect performance when assessed against all criteria, 
MLVA performs well overall. It scores high in its performance against several key criteria 
including discriminatory power, robustness, portability, objectivity and throughput [21,22], 
but scores low in versatility, since most protocols are species or serotype specific. 
Comparatively, pulsed-field gel electrophoresis (PFGE), the current gold standard method 
for the subtyping of food-borne bacterial pathogens, scores high in discriminatory power and 
versatility, but medium in robustness and low in portability, objectivity and throughput [22].
The historical success of PFGE for the inter-laboratory surveillance of food- and waterborne 
bacterial pathogens was based on the standardisation of methodology and interpretation 
through an internationally coordinated approach. The future success of emerging 
technologies such as MLVA for inter-laboratory surveillance similarly hinges on the 
coordinated harmonisation of the methodology, nomenclature and interpretation.
In this paper, we describe an international consensus for the development, validation, 
nomenclature, and quality control for MLVA-based inter-laboratory surveillance based on a 
review of the current state of science. These consensus guidelines were developed following 
an expert consultation in Copenhagen, Denmark, in May 2011, organised by the United 
States (US) Centers for Disease Control and Prevention (CDC), the European Centre for 
Disease Prevention and Control (ECDC), the Association of Public Health Laboratories in 
United States, the Public Health Agency of Canada and the Statens Serum Institut, 
Denmark.
Method development
Selection of potential loci
The first step in the development of an MLVA method involves the selection of potential loci 
for inclusion in the protocol. Initial VNTR locus finding and identification is performed by 
querying whole genome sequences using specialised software. Some VNTR-finding 
software is available free of charge on the Internet, and include Tandem Repeats Finder [23] 
and TredD [24]. Commercial software is also available and includes GeneQuest (DnaStar 
Lasergene, Madison, WI, US) and CodonCode (CodonCode Corp., Dedham, MA, US). 
Tandem Repeats database [25] is a public repository of information on tandem repeats and 
also contains a variety of tools for their analysis.
There is no standardised naming of loci used in MLVA schemes. In order to create 
uniformity in this context, it is proposed to name the loci in relation to their positions in the 
prototype genome. The proposed standardised locus naming (Box 1) and its correlation with 
existing nomenclature for loci that overlap between most published protocols for STEC 
O157, and S. Typhimurium and S. Enteritidis are outlined in Tables 1–3, respectively.
When selecting loci (Box 2), as a rule of thumb, the shorter the repeat unit, the more 
variation is detected in terms of copy numbers [26]. However, repeat units shorter than five 
bp should not be included in a subtyping system due to the limitations in sizing 
reproducibility in capillary electrophoresis platforms. It is critical to avoid repeat units with 
insertion and deletions (indels) in order to facilitate consistent sizing and allele naming using 
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copy numbers. Low-level base variation between repeat units does not usually have a 
negative impact as long as the unit length is consistent. However, perfect homogeneous 
repeats are always better and will usually also increase polymorphism through the effect of 
polymerase slippage [26]. Furthermore, only loci with 100% conserved flanking sequences 
in the target organism should be included.
Primer design
Once loci have been identified, primers for their PCR amplification need to be designed 
(Box 2). There are multiple choices for primer design software, both commercial and free of 
charge. The shareware version of the software FastPCR [27] works well. However, more 
elaborate versions of commercial software, such as VisualOmp (DNA Software, Inc, Ann 
Arbor, MI, United States), allow for performing simulations that will check for primer 
interactions in multiplex reactions; such checking is not available in the free software. At the 
very least, primer design software should be used to verify that no secondary structures, such 
as hairpins or self- and cross-dimers are formed between any of the primers intended to be 
multiplexed in the same reaction.
When designing primers, a number of issues need to be considered. Firstly, primers should 
be placed as close to the VNTR array as possible since the projected fragment size should 
not exceed 600 bp, which is the upper limit of reproducible sizing in most capillary 
electrophoresis platforms. This is particularly critical for VNTR arrays with long repeat 
units and for arrays with shorter repeat units combined with high diversity, in which scenario 
dozens of repeat units may be possible. If only a few prototype genomes are available, we 
suggest sequencing the flanking regions of each locus in 20 strains representative of the 
genetic diversity of the target organism in order to ensure that the primers are placed in 
conserved sequence. Secondly, the intended site of the primer should be targeted so that it 
falls in the most accurate region of the sequence, i.e. 80–150 bp away from the sequencing 
primer. Thirdly, the primers for all loci should have the same annealing temperature in order 
to facilitate easy multiplexing of targets in the same PCR reaction. Relatively high annealing 
temperatures of 55 °C to 65 °C should be aimed for to enable stringent amplification 
conditions for specific amplification. Generally, the melting temperature for primers should 
be 5 °C higher than the desired annealing temperature.
Assay optimisation
Once potential loci have been selected and primers designed, it is time to optimise the assays 
in the laboratory setting. This process includes testing the diversity of the loci selected and 
optimisation of the PCR reactions. This is an iterative process that is repeated until a set of 
loci with appropriate diversity have been selected and PCR conditions to amplify the loci 
reliably have been developed. Firstly, the VNTR loci should be screened for diversity using 
singleplex PCR reactions against a limited panel of 10 to 20 strains that are not related to 
each other and have been shown to be genetically diverse using other subtyping methods. At 
this stage, loci showing no diversity or minimal diversity are excluded from the assay. Also 
loci with poor amplification, multiple amplification products or background noise should be 
either excluded or the primers should be re-designed at this stage.
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After the initial screen, the promising VNTRs are tested against a larger panel (100–150) of 
isolates. This panel should contain both outbreak-related (information about patient 
exposures required) and epidemiologically unrelated (sporadic, i.e. different geographical 
locations, no temporal associations) isolates. This second screen will focus the selection 
process on VNTRs that generate epidemiologically relevant data. It also gives the assay 
developer an idea of the fragment size ranges in each locus, which is information that is 
needed for designing multiplex assays. Representative alleles in each locus, i.e. the smallest 
allele, the largest allele and at least every third in between, should be sequenced at the 
development phase in order to verify the copy number and to ensure that the size differences 
observed between different strains are due to differences in repeat unit copy numbers and not 
due to other genetic events.
Design of multiplex PCR reactions
Once the set of VNTR loci has passed the initial screening process, multiplex PCR reactions 
must be designed to enable efficient amplification of all loci in as few reactions as possible. 
Since the multiplex PCR reactions should be as robust as possible, no more than four or five 
targets should be amplified in the same reaction. Targets with overlapping fragment sizes 
can be differentiated using different fluorescent labels. The same label can be used multiple 
times in the same PCR reaction as long as there is no overlap in fragment sizes. The two 
main capillary electrophoresis platforms widely in use – Beckman Coulter CEQ8000/
GenomeLabGeXP Genetic Analysis System (Beckman Coulter, Brea, CA, United States) 
and Applied Biosystems Genetic Analyzer 3130/3730/3500 (Life technologies, Carlsbad, 
CA, United States) – differ vastly in the fluorescent chemistries that can be used and there is 
no overlap in the chemistries between them. Up to four different fluorescent labels can be 
detected simultaneously on the Beckman Coulter platform, whereas the Applied Biosystems 
instruments are capable of detecting up to five different fluorescent labels from the same 
reaction. One of the dyes is always reserved for the DNA size standard. Since it is highly 
desirable that protocols could be easily converted from one platform to another by simply 
just re-labelling the forward primers, use of more than three fluorescent labels for targets in 
the same reaction is therefore not recommended.
Important parameters to consider when designing the multiplex PCR reactions are the 
annealing temperature, MgCl2 concentration and primer concentration. Practical tips for 
approaches to optimise multiplex PCR reactions can be found in the literature [28].
All targets in the multiplex reaction should be easily detectable. The desired fluorescence 
intensity for PCR products on the Beckman Coulter platform is 5,000– 80,000 units, on the 
Applied Biosystems 3130 platform 1,000–7,000 units and on the Applied Biosystems 3500 
and 3730 platforms 2,000–9,000 units. Fluorescence intensity below the desirable level will 
result in unreliable detection of targets. Too high fluorescence intensity will cause 
fluorescence carry-over from one channel to another resulting in non-specific peaks that can 
interfere with the data analysis in downstream applications. If the same protocol is used in 
multiple laboratories, each laboratory typically needs to optimise the primer concentrations 
for their own laboratory since there are several laboratory-specific factors, such as the age of 
the primer stocks, the type and the calibration status of the thermocycler, which affect the 
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amplification efficiency. Additionally, as the primer stocks age, there is a gradual drop in the 
fluorescence intensity, requiring further optimisation of primer concentrations over time, 
even within the same laboratory.
Internal validation
When a prototype of the MLVA protocol has been established, it needs to go through 
internal validation (Box 3). The purpose is to test the robustness and reproducibility and to 
establish the discriminatory power of the method when used in the laboratory (or 
laboratories) that developed it.
The internal validation should be comprised of two phases, which may be performed 
simultaneously: (i) testing of additional isolates by the protocol developers; (ii) testing of the 
protocol by other laboratories/ individuals within the developers’ institutions for technical 
performance. The number of isolates to be tested during internal validation depends on the 
genetic diversity of the target organism, i.e. the higher the diversity, the more isolates are 
needed for adequate validation. Optimally 250 to 500 isolates, in addition to those that were 
tested during the development phase, should be tested. If the developing laboratory does not 
have access to such a large culture collection, the isolates must be acquired from 
collaborating laboratories. Insufficiently validated protocols should not be published in the 
scientific literature since they almost invariably will need further optimisation by future 
users. By analysing a large number of isolates using the proposed protocol, the robustness of 
the assay can be tested, along with its ability to consistently produce profiles from all strains 
and generate data that are epidemiologically relevant and easy to analyse. The strains used 
for the validation should include well-defined sets of both outbreak-associated isolates and 
sporadic isolates. The outbreak-associated isolates should also include 20 to 30 isolates from 
the same outbreak and ideally from multiple outbreaks of different types (monoclonal vs 
polyclonal, short lasting vs long lasting). Multiple isolates obtained through serial passaging 
of the same strain may also be included to test the reproducibility of the method and in vitro 
stability of the loci. If desired, the sporadic isolates and one representative from each 
outbreak can be used to calculate the diversity index for the method [29]. If the protocol is 
intended for global use, geographically representative isolates around the globe should be 
included in the validation set. Data generated with the proposed MLVA method should be 
compared with the epidemiological data in order to determine concurrence. Comparisons 
with the gold-standard method should also be made, if a gold standard exists for the target 
organism. In order to determine the technical performance, the protocol should be tested 
using multiple different equipment brands (thermocyclers, capillary electrophoresis 
instruments), different lots of reagents and by multiple individuals. All null alleles (= no 
amplification) should be confirmed using singleplex PCR reactions in order to rule out 
suboptimal multiplex conditions as a cause for amplification failure.
Calibration set and allele nomenclature
Inter-laboratory comparability, as mentioned before, is of critical importance if the 
subtyping method is to be used for international surveillance. Determining the number of 
repeats using different detection platforms without sequencing all amplicons is not reliable 
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because of use of different reagents, chemistries and detection platforms may yield slightly 
but sufficiently different fragment sizing results to hamper inter-laboratory comparisons 
[30,31]. Using different primers for amplification of the same loci will also invariably lead 
to lack of comparability of results generated in different laboratories. We propose to solve 
this problem by introducing organism-specific set of strains with well-characterised copy 
numbers at each locus that each laboratory implementing the method may use to calibrate 
the output of the protocol and detection platform they use (Boxes 4 and 5).
These strain calibration sets should be created both for existing MLVA protocols and for 
those developed in the future. The validation of such a calibration set for use with S. 
Typhimurium protocols is described in this issue of Eurosurveillance [32]. Each laboratory 
will use the calibration set to create a correlation table between the sequenced copy number 
and the observed fragment size for each allele at each locus using their preferred protocol 
and fragment-sizing platform. This way, the same allele type will always be assigned to the 
same fragment regardless of the primer sequences, reagents or capillary electrophoresis 
platform used to generate and size the fragment. The calibration should be repeated each 
time a laboratory changes any parameter in its MLVA set-up, such as using a different 
fluorescent dye for a primer or different type of polymer for capillary electrophoresis. The 
calibration set should cover representative alleles for all loci included in the new protocol, 
and in the case of the existing protocols, for those loci that overlap between the protocols 
that are already widely used. All VNTR loci should be sequenced for all isolates included in 
the calibration set in order to determine the actual copy number. All alleles should be 
included in the calibration set if the VNTR locus contains four or fewer alleles. If the VNTR 
locus contains five or more alleles it is proposed that at least the smallest and the largest 
alleles and every third allele in between should be included in the calibration set. All new 
alleles with unexpected fragment sizes (fragment sizes that do not fall within predicted sizes 
for new alleles based on the calibration set) must be sequenced, and, if needed, the 
calibration set should be amended.
If multiple peaks are detected in the same locus, the PCR needs to be repeated using a fresh 
DNA template made from a culture derived from a single colony in order to exclude the 
possibility of contamination, since this is the most common explanation for this 
phenomenon. If contamination is not the cause of the problem and the result with multiple 
peaks is reproducible, with the same peak always having the highest fluorescence intensity, 
then the allele type should be designated based on the most intense peak and the other peaks 
should be ignored if the locus cannot be excluded from the assay. If upon repeating the PCR 
the same peak does not always present with the highest fluorescence intensity, 10 colony 
picks should be tested from the culture. In this case, the allele type should be assigned based 
on the peak that has the highest fluorescence intensity in the majority of the colony picks.
External validation
When the method has passed the internal validation, it needs to be validated by the future 
external users. The purpose of external validation is to determine the robustness and 
performance of the methodology and thereby the feasibility of implementing it in multiple 
laboratories of end users (Box 6).
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It is important that results from different laboratories in diverse geographical locations and 
with different skill levels are compatible and reproducible for international surveillance and 
outbreak detection and investigations. It is expected that different laboratories may use 
reagents from different suppliers. Often equipment in different laboratories is made by 
different manufacturers or different models from the same manufacturer are used. Although 
MLVA results are less prone to variability arising from subjective interpretation by trained 
laboratory staff, it is nevertheless important to take proficiency of data interpretation into 
consideration. In particular, the consistency of person-to-person interpretation of partial 
repeats and null alleles should be assessed, as should unpredicted results. In order to 
maintain consistency of results over time, quality assurance processes should also be 
considered after the external validation.
In selecting suitable laboratories to participate in the external validation, a survey containing 
questions in regard to testing capacity could be distributed to reference laboratories that have 
been performing PFGE or other molecular typing methods for cluster detection. Such a 
survey will also explore the global interest in using the method.
The aim of inter-laboratory comparison is to determine the variability of the results obtained 
by different laboratories using identical samples. Six to eight laboratories should be selected 
from different geographical locations that may have different endemic or outbreak strains 
with profiles determined using the gold-standard method and have the capacity to perform 
MLVA. These laboratories should cover the range of equipment platforms (including 
different manufacturers, models and analytical software) and reagents from different 
suppliers. It is preferable that the participating laboratories have trained microbiologists 
available who are knowledgeable in capillary electrophoresis for troubleshooting and 
interpretation of results.
The selected laboratories should initially test the calibration set of strains using the same 
procedures that have been internally validated to create the calibration table for standardised 
reporting. In addition, for comparing inter-laboratory compatibility, each laboratory needs to 
subtype a blinded set of at least 20 well-characterised strains supplied by the organising 
laboratory and covering the full spectrum of alleles at all loci, including alleles that are not 
present in the calibration set. The results from all the participating laboratories should be 
distributed and shared by the organising laboratory. The concordance is calculated for the 
study overall and for each individual laboratory. Discordant results must be resolved and 
recommendations on corrective actions to improve concordance be made. These corrective 
actions should be provided to future participants as part of quality assurance of the method. 
If the concordance was poor initially (discordant results generated for more than 5% of the 
isolates in more than 20% of the participating laboratories), the external validation may need 
to be repeated with any corrections to the protocol.
When good concordance has been achieved between the laboratories, each participant 
should test additional strains selected from its own culture collection that has been well 
characterised, ideally using the same gold-standard method, typically PFGE. These strains 
should be from diverse locations and epidemiological backgrounds. The number of strains 
will typically be between 50 and 100, depending on the diversity of the target organism. This 
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panel should be well defined to evaluate typeability, i.e. the ability to amplify each locus, the 
discriminatory power and epidemiological concordance of the method [21]. It must include 
strains from human and non-human sources, and contain a mix of epidemiologically 
unrelated and related isolates. The MLVA testing should be evaluated for these criteria in 
comparison with the gold standard, if such a method exists.
If new alleles are encountered during the external validation, strains with these alleles should 
be shared with the developing laboratory for confirmation by sequencing. If necessary, the 
calibration set should be revised to ensure that the copy number of the new alleles can be 
determined reliably. The external validation laboratories should also test the strains thus 
added to the calibration set, to update their correlation tables.
Quality assurance
The final step before an MLVA protocol may be implemented in routine surveillance in 
multiple laboratories is the establishment of a quality assurance programme for future users 
(Box 7). Quality assurance is divided into internal and external sections.
Internal quality assurance includes the use of appropriate controls for PCR and fragment 
analysis, quality control of new primer lots, maintenance and calibration of instruments, 
such as thermocyclers and pipettors, and appropriate record keeping for monitoring reagent 
lots, instrument performance and run-to-run accuracy of sizing. An internal training 
programme should be in place as part of the human resource succession or continuity plan 
and for surge capacity. Newly trained personnel should be assessed for proficiency prior to 
assuming routine testing and then assessed annually internally. Each laboratory should also 
participate in external quality assurance (EQA), if available.
EQA includes initial and annual quality checks performed by a laboratory/institute that has 
agreed to serve as a coordinating quality assurance body for the protocol in question. When 
a protocol is used in an international surveillance network such as PulseNet, new 
participants are certified for the laboratory procedure and the correct data analysis and 
reporting of the results for a limited set of well-characterised strains as part of the initial 
quality check. Once certified, each laboratory needs to pass a proficiency test at least 
annually to keep their certification status [22]. Valid certification is required from each 
laboratory in order to be able to upload data to the PulseNet databases. In PulseNet 
International, the coordinating laboratory in each region is responsible for the EQA in their 
respective region and the US CDC performs the EQA for the coordinating laboratories. 
ECDC has funded an external voluntary EQA scheme for MLVA of S. Typhimurium for the 
public health laboratories in the European Union and European Economic Area countries. 
This is a new quality assessment scheme in Europe that does not provide a formal 
certification status but serves as ‘shelf-check’ for the participants. The first results are 
expected to be available in 2013.
The developing laboratory typically selects a set of strains to be used for certification and 
proficiency testing. The number of strains used for certification of new users and proficiency 
testing of current users depends on the clonality of the organism. PulseNet US’s certification 
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sets for MLVA include eight isolates, and proficiency testing is performed by testing only a 
single isolate in the same test run with each laboratory’s routine isolates. The generated data 
are evaluated not only for correct patterns but also for the overall quality of data, e.g. non-
specific peaks, primer-dimers and optimisation of PCR reactions.
Successful implementation of a new MLVA protocol may be facilitated through training of 
new users. This training needs to include the use of the detection platform the participants 
will use in their own laboratory, to make them familiar with the protocol in a setting as close 
as possible to the one they will use in the future.
Concluding remarks
It is our hope that the guidelines and recommendations presented here will help solve some 
of the problems hampering the inter-laboratory comparisons of MLVA subtyping results, 
provide clarification of the relationships between the multiple protocols currently available 
for STEC O157, S. Enteritidis and S. Typhimurium, and facilitate the development and 
validation of new MLVA protocols for organisms not covered by currently available 
protocols.
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Standardised VNTR locus nomenclature for an MLVA protocol
A VNTR locus is named based on its location on the chromosome on the prototype 
genome by the closest kilobase (kb). If located on a plasmid, the name of the plasmid is 
used instead of the prototype genome.
Example: the standardised name of the Salmonella enterica serovar Typhimurium VNTR 
locus STTR6 [18] would be STM2730, i.e. STM is the designation for the Typhimurium 
prototype genome LT2 and 2730 is the closest kb location for the locus STTR6 on the 
LT2 genome.
MLVA: multiple-locus variable-number of tandem-repeats analysis; STEC: Shiga toxin-
producing Escherichia coli; VNTR: variable-number tandem repeat.
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Optimal VNTR locus and primer selection for developing an MLVA protocol
• Repeat units ≥5 base pairs
• No insertions and deletions in repeat units
• Perfect homogeneous repeats should be preferred
• Only loci with 100% conserved flanking sequences should be used
• Primers should be placed as close as possible to the VNTR unit
• Primers with relatively high annealing temperatures (55 °C to 65 °C) should 
be used
• The melting temperature should be 5 °C higher than the annealing 
temperature
• No more than three fluorescent dyes should be used to label the primers used 
in the assay
MLVA: multiple-locus variable-number of tandem-repeats analysis; VNTR: variable-
number tandem repeat.
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Internal validation of an MLVA prototype protocol
• Purpose: to obtain information about the robustness, reproducibility, 
discriminatory power and epidemiological concordance in the laboratory (or 
laboratories) involved in the protocol development
• Comparison with gold-standard method, e.g. PFGE, if such a method is 
available
• Isolate selection should:
○ include 250–500 isolates o include sporadic isolates and multiple 
isolates from several outbreaks, to test in vivo stability
○ include serially passaged isolates from one strain, to test in vitro 
stability
○ be representative of the intended epidemiological context, e.g. 
geographical region, institutions/community
MLVA: multiple-locus variable-number of tandem-repeats analysis; PFGE: pulsed-field 
gel electrophoresis.
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Proposed standardised allele nomenclature and reporting of allele profiles 
for an MLVA protocol
Proposed standardised allele nomenclature for homogeneous VNTRs
• The allele name is the actual sequenced copy number
• Incomplete repeats: the copy number rounded down to the nearest complete 
copy number
• Null alleles: the designated allele type ‘−2.0’
• VNTR array missing, but the flanking region with the primer-annealing 
sequences present and amplifies: the designated allele type ‘0’
Proposed standardised allele nomenclature for heterogeneous VNTRs
• Inclusion of loci with heterogeneous repeat units is discouraged in new 
protocols
• Some existing protocols include heterogeneous loci, such as the locus STTR3 
in the Salmonella enterica serovar Typhimurium protocol by Lindstedt et al. 
[19]. STTR3 consists of 27 bp and 33 bp repeat units.
• Allele type should indicate copy numbers of all different length repeat units.
○ Example: for STTR3, the allele type 0208 corresponds to two 
copies of the 27 bp repeat unit and eight copies of the 33 bp repeat 
unit [36].
Proposed standardised reporting of allele profiles
• New protocols: reported in the order the loci are located in genome. Loci 
located on plasmids reported last.
• Existing protocols: the currently most widely accepted reporting order for loci 
will be continued.
○ Example: the S. Typhimurium MLVA profile reported in the locus 
order STTR9-STTR5-STTR6-STTR10-STTR3: 3-8-13-14-0411
bp: base pair; MLVA: multiple-locus variable-number of tandem-repeats analysis; VNTR: 
variable-number tandem repeat.
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Calibration strain set for developing an MLVA protocol
• Purpose: a reference set of strains with diverse confirmed number of repeats 
at all loci to be used to create a calibration table enabling correct allele 
designation in the test laboratories
• Strain selection:
○ all alleles have been confirmed by sequencing
○ for loci with up to four alleles, all alleles must be represented
○ for loci with five or more alleles, the smallest, the largest and at 
least every third allele in between must be represented
• If a new allele is identified, its copy number must be confirmed by sequencing
○ If a strain contains a new allele outside the range of known alleles, it 
must be added to the calibration strain set
• A new calibration table should be generated by testing the full calibration 
strain set when new instruments or chemistries are introduced
MLVA: multiple-locus variable-number of tandem-repeats analysis.
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External validation of an MLVA prototype protocol
• Purpose: to confirm the robustness, reproducibility, discriminatory power and 
epidemiological concordance, and thereby the feasibility of implementing the 
method in multiple laboratories representing the intended end users
• Six to eight laboratories representing the full diversity of intended end users 
should be selected. They should:
○ be from different geographical locations
○ have a full range of equipment platforms
○ have supplies from different manufacturers
• Each laboratory should test:
○ the calibration strain set, to create the calibration table
○ a minimum of 20 isolates representing the full known allelic 
diversity at all loci. If discordant results are generated in >5% of the 
isolates in >20% of the participating laboratories, the protocol and 
of the calibration isolate set should be revisited and corrected, and 
the external validation repeated
○ 50–100 strains from each participating laboratory representing the 
local diversity of the organism
MLVA: multiple-locus variable-number of tandem-repeats analysis.
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Quality assurance and proficiency testing of an MLVA prototype protocol
Quality assurance
• Purpose: to ensure consistent high quality of the results generated
• Control strains should be included for PCR and fragment analysis in each run
• Multiple reference strains should be run as a quality control check when new 
primer lots are introduced or after any major maintenance or repair of the 
instrument
• Records of reagent lots and accuracy of fragment sizing for control strains 
should be maintained for each run
• An internal training programme should be in place for new personnel
Proficiency testing
• If available, participation in an external quality assurance programme is 
mandatory
• Newly trained personnel must pass an initial test for proficiency and be tested 
annually thereafter
• Assessment of proficiency includes generation of correct allele profiles and 
overall quality of data, e.g. presence of non-specific peaks, primer-dimers and 
other PCR artifacts
MLVA: multiple-locus variable-number of tandem-repeats analysis; PCR: polymerase 
chain reaction.
Nadon et al. Page 19













Figure. Typical organisation of a variable number of tandem repeat (VNTR) locus
The arrows point to the annealing sites for polymerase chain reaction (PCR) primers in the 
conserved region flanking the repeats.
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Table 2
Nomenclature for overlapping VNTR loci in published MLVA protocols for Salmonella enterica serovar 
Typhimurium
Standardised VNTR locus namea
Nomenclature used in published MLVA protocol
Lindstedt [19] Witonski [20] Chiou [18] PulseNet US [17]
STM2730 STTR6 2730867 ST19 ST5
STM3184 STTR5 3184543 ST25 ST6
STM3246 STTR9 NA ST26 ST7
STM3629 STTR3 3629542 ST06 ST8
pSLT53 STTR10 NA ST40 STTR10
MLVA: multiple-locus variable-number of tandem-repeats analysis; NA: not applicable; VNTR: variable-number tandem repeat.
a
Prototype genome described by McClelland et al. [34].
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